Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease

Therapeutic Drug Monitoring

Volumn 35, Issue 4, 2013, Pages 530-538

  Steenholdt, Casper ^a   Ainsworth, Mark A ^a   Tovey, Michael ^b   Klausen, Tobias W ^a   Thomsen, Ole Ø ^a   Brynskov, Jørn ^a   Bendtzen, Klaus ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Ecole Normale Superieure de Cachan   (France)

^c Copenhagen University Hospital   (Denmark)

Author keywords

ELISA; inflammatory bowel disease; RGA; RIA; TNF

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN G4; INFLIXIMAB;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUID PHASE RADIOIMMUNOASSAY; HUMAN; LIMIT OF DETECTION; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REPORTER GENE ASSAY; SOLID PHASE ENZYME LINKED IMMUNOSORBENT ASSAY;

ANTIBODIES; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIMIT OF DETECTION; RADIOIMMUNOASSAY;

EID: 84880570843     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828d23c3     Document Type: Article

References (31)

1. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007;133:312-339.
2. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355-366.
3. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
4. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774-781.
5. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139.
6. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
7. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
8. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
9. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60:41-48.
10. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275.
11. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20:431-435.
12. Bendtzen K. Immunogenicity of anti-TNF antibodies. In: van de Weert M, Møller EH, eds. Biotechnology: Pharmaceutical Aspects Vol. VIII. Immunogenicity of Biopharmaceuticals. Springer: New York; 2008: 189-203.
13. Lallemand C, Kavrochorianou N, Steenholdt C, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373:229-239.
14. Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992;27:609-614.
15. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363.
16. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948.
17. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol. 2011;46:310-318.
18. Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2209-2217.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
20. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169-174.
21. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
22. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-3789.
23. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46: 1828-1834.
24. Bendtzen K, Svenson M. in: Tovey MG, eds. Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied. West Sussex, United Kingdom: John Wiley & Sons Ltd; 2011.
25. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
26. Wang S, Ohrmund L, Singh S. Measurement of human anti-chimeric antibodies (Haca) and infliximab levels in paitent serum using a novel homogeneous assay. Gastroenterology. 2010;138:S-684.
27. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol. 2012;47:136-143.
28. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372:196-203.
29. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
30. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
31. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis. 2012;18:1628-1633.